# Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

> **NCT00681395** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 64 (actual)

## Conditions studied

- Adverse Events
- Pharmacokinetic

## Interventions

- **DRUG:** ABT-143
- **DRUG:** ABT-335
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT00681395
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2012-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681395, "Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00681395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*